Treatments in Respiratory Medicine

, Volume 5, Issue 3, pp 181–191

Taxanes in the Treatment of Non-Small Cell Lung Cancer

Review Article

Abstract

Paclitaxel and docetaxel, drugs that bind tightly to β-tubulin and disrupt microtubule dynamics, are widely used in the treatment of non-small cell lung cancer (NSCLC), the most common cause of cancer death in men and women living in the US. These well tolerated drugs, alone or in combination with another cytotoxic agent, have been shown to increase the survival of patients with metastatic disease or malignant effusions. Both paclitaxel and docetaxel can be combined with concurrent chest irradiation for patients with locally advanced NSCLC. The combination of carboplatin and paclitaxel, when given postoperatively to patients with stage IB NSCLC, improved survival compared with surgery alone, with little toxicity. Taxane combinations are undergoing study as adjuvant therapy for patients with other stages of operable disease. Except for a recent trial with bevacizumab, efforts to improve the efficacy of taxane/platinum combinations in patients with advanced disease by adding a third ‘targeted’ drug have thus far been unsuccessful.

References

  1. 1.
    Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5–26PubMedCrossRefGoogle Scholar
  2. 2.
    Bailey-Wilson JE, Arnos CI, Pinney SM, et al. A major lung cancer susceptibility locus maps to chromosome 6q23–25. Am J Hum Genet 2004; 75: 460–74PubMedCrossRefGoogle Scholar
  3. 3.
    Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354: 333–42PubMedCrossRefGoogle Scholar
  4. 4.
    Page N, Read W, Tierney M, et al. The epidemiology of small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 2002; 21: 210Google Scholar
  5. 5.
    Minna JD, Fong K, Zochbauer-Muller S, et al. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J 2002; 8 Suppl. 1: 41-6Google Scholar
  6. 6.
    Danesi R, De Braud F, Fogli S, et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 2003; 55: 57–103PubMedCrossRefGoogle Scholar
  7. 7.
    Thomas J, Lynch DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350(21): 2129–39CrossRefGoogle Scholar
  8. 8.
    Rowinsky EK, Onetto N, Canetta RM, et al. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19(6): 646–62PubMedGoogle Scholar
  9. 9.
    Giannakakou P, Nakano M, Nicolaou K, et al. Enhanced microtubule-dependent trafficking and p53 nuclear accumulation by suppression of microtubule dynamics. Proc Natl Acad Sci U S A 2002; 99: 10855–60PubMedCrossRefGoogle Scholar
  10. 10.
    Leonard G, Fojo T, Bates S. The role of ABC transporters in clinical practice. Oncologist 2003; 8: 411–24PubMedCrossRefGoogle Scholar
  11. 11.
    Rosell R, Taron M, Alberola V, et al. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003; 41 Suppl. 1: S97-102Google Scholar
  12. 12.
    Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer. Oncogene 2003; 22(23): 3548–53PubMedCrossRefGoogle Scholar
  13. 13.
    Giannakakou P, Sackett D, Kang Y, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272: 17118–25PubMedCrossRefGoogle Scholar
  14. 14.
    Kelley M, Li S, Harpole D. Genetic analysis of the beta-tubulin gene, TUBB, in non-small cell lung cancer. J Natl Cancer Inst 2001; 93: 1886–8PubMedCrossRefGoogle Scholar
  15. 15.
    Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004; 5(3): 158–64PubMedCrossRefGoogle Scholar
  16. 16.
    Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22(19): 3852–9PubMedCrossRefGoogle Scholar
  17. 17.
    Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19–21PubMedCrossRefGoogle Scholar
  18. 18.
    Stephens RJ, Fairlamb D, Gower N, et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC): preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 2002; 21: 1161aGoogle Scholar
  19. 19.
    Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 2000; 92: 1074–80PubMedCrossRefGoogle Scholar
  20. 20.
    Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27(3): 145–57PubMedCrossRefGoogle Scholar
  21. 21.
    Lilenbaum RC, Herndon 2nd JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the Cancer and Leukemia Group B. J Clin Oncol 2005; 23: 190–6PubMedCrossRefGoogle Scholar
  22. 22.
    Georgoulias V, Ardavanis A, Agelidou M, et al. Preliminary analysis of multicenter phase III trial comparing docetaxel versus docetaxel/cisplatin in patients with inoperable advanced and metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2002; 21: 291aGoogle Scholar
  23. 23.
    Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer. JAMA 2004; 292(4): 470–84PubMedCrossRefGoogle Scholar
  24. 24.
    Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18(3): 623–31PubMedGoogle Scholar
  25. 25.
    Kelly K. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non—small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 2001; 19: 3210–8PubMedGoogle Scholar
  26. 26.
    C. Belani CP, Larocca RV, Renaldi DA, et al. A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin vs. standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel. Proc Am Soc Clin Oncol 2004; 22: 621sGoogle Scholar
  27. 27.
    Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92–8PubMedCrossRefGoogle Scholar
  28. 28.
    Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21(16): 3016–24PubMedCrossRefGoogle Scholar
  29. 29.
    Smit EF, van Meerbeeck JP, Lianes P, et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003; 21(21): 3909–17PubMedCrossRefGoogle Scholar
  30. 30.
    Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13(10): 1539–49PubMedCrossRefGoogle Scholar
  31. 31.
    Dillman R, Seagren S, Propert K, et al. A randomized trial of induction chemotherapy plus high-dose radiation vs radiation alone in stage III non-small cell lung cancer. N Engl J Med 1990; 323: 940–5PubMedCrossRefGoogle Scholar
  32. 32.
    Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable Stage III nonsmall cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the ECOG. J Clin Oncol 1999; 17: 4–11PubMedGoogle Scholar
  33. 33.
    Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone vs combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer. J Natl Cancer Inst 1991; 83: 417–23PubMedCrossRefGoogle Scholar
  34. 34.
    Schaake-Konig C, Van dan Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 524–30CrossRefGoogle Scholar
  35. 35.
    Sause W, Kolesar P, Taylor S, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: radiation therapy oncology group, eastern cooperative oncology group and southwest oncology group. Chest 2000; 117: 358–64PubMedCrossRefGoogle Scholar
  36. 36.
    Soresi E, Clerici M, Grilli R, et al. A randomized clinical trial comparing radiation therapy v radiation therapy plus cis-dichlorodiamine platinum in the treatment of locally advanced non-small cell lung cancer. Semin Oncol 1998; 15: 20–5Google Scholar
  37. 37.
    Jeremec B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: a randomized study. J Clin Oncol 1996; 14: 1065–70Google Scholar
  38. 38.
    Marino P, Preatoni A, Cantoni A, et al. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIA and IIIB nonsmall cell lung cancer: a met-analysis. Cancer 1995; 76: 593–601PubMedCrossRefGoogle Scholar
  39. 39.
    Dillman R, Herndon J, Seagren S, et al. Improved survival in stage III non-small cell lung cancer: seven-year followup of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210–5PubMedCrossRefGoogle Scholar
  40. 40.
    Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17(9): 2692–9PubMedGoogle Scholar
  41. 41.
    Curran W, Scott C, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer: Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2003; 22: 621aGoogle Scholar
  42. 42.
    Pierre F, Maurice P, Gilles R, et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemoradiotherapy in locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2001; 20: 312aGoogle Scholar
  43. 43.
    Vokes EE, Herndon JE, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small cell lung cancer: Cancer and Leukemia Group B study 9431. J Clin Oncol 2002; 20: 4191–8PubMedCrossRefGoogle Scholar
  44. 44.
    Kiura K, Ueoka H, Segawa Y, et al. Phase I/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 2003; 89(5): 795–802PubMedCrossRefGoogle Scholar
  45. 45.
    Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: a randomized phase II locally advanced multimodality protocol. J Clin Oncol 2005; 23: 5883–91PubMedCrossRefGoogle Scholar
  46. 46.
    Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21(10): 2004–10PubMedCrossRefGoogle Scholar
  47. 47.
    Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small-cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004; 23: 618sGoogle Scholar
  48. 48.
    Keller SM, Adak S, Wagner H, et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer. N Engl J Med 2000; 343: 1217–22PubMedCrossRefGoogle Scholar
  49. 49.
    Scagliotti GV, Fossati R, Torri V, et al. Randomized trial of adjuvant chemotherapy for completely resected stage I, II or IIIA non small lung cancer. J Natl Cancer Inst 2003; 95: 1453–61PubMedCrossRefGoogle Scholar
  50. 50.
    Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351–60PubMedCrossRefGoogle Scholar
  51. 51.
    Winton TL, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs observation in resected non-small cell lung cancer. N Engl J Med 2005; 352: 2589–97PubMedCrossRefGoogle Scholar
  52. 52.
    Strauss GM, Hernton J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small-cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) Protocol 9633. Proc Am Soc Clin Oncol 2004; 23: 621sGoogle Scholar
  53. 53.
    Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 1994; 330: 153–8PubMedCrossRefGoogle Scholar
  54. 54.
    Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 1994; 86: 673–80PubMedCrossRefGoogle Scholar
  55. 55.
    Rosell R, Gomez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small cell lung cancer: a seven year assessment of a randomized controlled trial. Lung Cancer 1999; 26: 7–14PubMedCrossRefGoogle Scholar
  56. 56.
    Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. Lung Cancer 1998; 21: 1–6PubMedCrossRefGoogle Scholar
  57. 57.
    Albain KS, Scott CB, Rusch VR, et al. phase III comparison of concurrent chemotherapy plus radiotherapy (ct/rt) and ct/rt followed by surgical resection for stage iiia (pn2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09). Proc Am Soc Clin Oncol 2003; 22: 386Google Scholar
  58. 58.
    Pisters KM, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early stage lung cancer: a novel approach. J Thorac Cardiovasc Surg 2000; 119: 429–39PubMedCrossRefGoogle Scholar
  59. 59.
    Spira A, Ettinger D. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350: 379–2PubMedCrossRefGoogle Scholar
  60. 60.
    Hainsworth JD, Thompson DS, Greco FA, et al. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol 1995; 13: 1609–14PubMedGoogle Scholar
  61. 61.
    Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 2002; 38 Suppl. 4: 5-12Google Scholar
  62. 62.
    Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18(10): 2095–103PubMedGoogle Scholar
  63. 63.
    Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18(12): 2354–62Google Scholar
  64. 64.
    Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22(9): 1589–97PubMedCrossRefGoogle Scholar
  65. 65.
    Williamson SK, Crowley JJ, Lara PN, et al. S0003: paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). a phase 3 Southwest Oncology Group (SWOG) trial [abstract no. 2502]. Proc Am Soc Clin Oncol 2003 May 31, 622Google Scholar
  66. 66.
    Levitzki A. EGF receptor as a therapeutic target. Lung Cancer 2003; 41 Suppl. 1: S9–S15PubMedCrossRefGoogle Scholar
  67. 67.
    Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotnib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123–32PubMedCrossRefGoogle Scholar
  68. 68.
    Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial— INTACT 2. J Clin Oncol 2004; 22(5): 785–94PubMedCrossRefGoogle Scholar
  69. 69.
    Herbst RS, Prager D, Hermann R, et al. Tribute: a phase III trial of erlotinib combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2005; 23: 5892–9PubMedCrossRefGoogle Scholar
  70. 70.
    Shi B, Yaremko B, Hajian G, et al. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000; 46(5): 387–93PubMedCrossRefGoogle Scholar
  71. 71.
    Khuri FR, Glisson BS, Kim ES, et al. Phase 1 Study of the farnesyl transferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004 May 1; 10(9): 2968–76PubMedCrossRefGoogle Scholar
  72. 72.
    Blumenschein Jr G, Ludwig C, Thomas G, et al. A randomized phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer [abstract]. 11th World Congress on Lung Cancer, International Association for Study of Lung Cancer; 2005 July 3–6; Barcelona, Spain [online]. Proceedings available at URL: http://www.IASLC.org [Accessed 2006 Apr 14]
  73. 73.
    Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel along in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184–91PubMedCrossRefGoogle Scholar
  74. 74.
    Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer [abstract]. J Clin Oncol 2005; 23 Suppl. 16: LBA4Google Scholar
  75. 75.
    Fannucchi MP, Fossella F, Fidias P, et al. Bortezomib +/- docetaxel in previously treated patients with advanced non-small cell lung cancer: a phase 2 study [abstract]. J Clin Oncol 2005; 23 Suppl. 16: 7034Google Scholar
  76. 76.
    Lynch T, Raju R, Lind M, et al. Randomized phase III trial of chemotherapy and antisense nucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC [abstract]. Proc Am Soc Clin Oncol 2003; 22: 22Google Scholar
  77. 77.
    Laskin J, Sandier A. The importance of the eicosanoid pathway in lung cancer. Lung Cancer 2003; 41 Suppl. 1: S73–81PubMedCrossRefGoogle Scholar
  78. 78.
    Wolff A, Donehower R, Carducci M, et al. Phase I study of Docosahexanoic Acid-Paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin Cancer Res 2004; 9: 3589–97Google Scholar
  79. 79.
    Kosmidis P, Manegold C. Advanced NSCLC: new cytostatic agents. Lung Cancer 2003; 41 Suppl. 1: S123–33PubMedCrossRefGoogle Scholar

Copyright information

© adis data information BV 2006

Authors and Affiliations

  1. 1.Winship Cancer Institute at Crawford Long HospitalEmory University School of MedicineAtlantaUSA

Personalised recommendations